SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.0B
Q1 2024
Positions
59
Filings on Record
27
2019–present window
Filed
May 15, 2024
original filing

Summary

Boxer Capital, LLC reported $2.0B in U.S.-listed holdings across 59 positions for Q1 2024.

Its largest position, SWTXUSD, represents 8.3% of the portfolio.

Compared with Q4 2023, the fund opened 13 new positions and exited 6.

Portfolio Metrics

Turnover
+23.7%
vs prior filed quarter
Top-10 Concentration
+53.8%
share of reported value
Largest Position
+8.3%
Springworks Therapeutics
New / Exited
13 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 84.9%ADR: 8.3%Other: 6.6%ETP: 0.1%Equity WRT: 0.0%
  • Common Stock · 84.9% · $1.7B
  • ADR · 8.3% · $168M
  • Other · 6.6% · $134M
  • ETP · 0.1% · $3M
  • Equity WRT · 0.0% · $82,833

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VKTXViking Therapeutics IncNEW+300.0K300.0K+$25M$25M
KURAKura Oncology IncNEW+1.00M1.00M+$21M$21M
ALLOAllogene Therapeutics IncNEW+3.85M3.85M+$17M$17M
SANASana Biotechnology IncNEW+1.54M1.54M+$15M$15M
PSTXUSDPoseida Therapeutics IncNEW+4.47M4.47M+$14M$14M
Engene Holdings IncNEW+727.9K727.9K+$12M$12M
JSPRJasper Therapeutics IncNEW+350.0K350.0K+$10M$10M
BOLDBoundless Bio IncNEW+711.3K711.3K+$10M$10M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SWTXUSDSpringworks Therapeutics Inchistory →COM8.32%$168M3.42M
2CYTKCytokinetics Inchistory →COM NEW7.27%$147M2.10M
3RVMDRevolution Medicines Inchistory →COM6.81%$138M4.28M
4TYRATyra Biosciences Inchistory →COM5.22%$106M6.45M
5APLSUSDApellis Pharmaceuticals Inchistory →COM5.01%$101M1.73M
6IDYAIdeaya Biosciences Inchistory →COM4.77%$97M2.20M
7Merus N VCOM4.23%$86M1.90M
8SRPTSarepta Therapeutics Inchistory →COM4.16%$84M650.0K
9NUVLNuvalent Inchistory →COM4.15%$84M1.12M
10ONCBeiGene Ltdhistory →SPONSORED ADR3.86%$78M500.0K
11TNGXTango Therapeutics Inchistory →COM3.22%$65M8.20M
12NKTXNkarta Inchistory →COM2.99%$61M5.61M
13FATEFate Therapeutics Inchistory →COM2.98%$60M8.22M
14RNAGBPAvidity Biosciences Inchistory →COM2.18%$44M1.73M
15AKROAkero Therapeutics Inchistory →COM2.09%$42M1.68M
16RCKTRocket Pharmaceuticals Inchistory →COM1.95%$39M1.47M
17ARGXArgenx SEhistory →SPONSORED ADR1.94%$39M100.0K
18LEGNLegend Biotech Corphistory →SPONSORED ADS1.66%$34M600.0K
19AXSMAxsome Therapeutics Inchistory →COM1.58%$32M400.0K
20RCUSArcus Biosciences Inchistory →COM1.49%$30M1.60M
21ANABAnaptysBio Inchistory →COM1.45%$29M1.30M
22IMVTImmunovant Inchistory →COM1.32%$27M825.0K
23XENEXenon Pharmaceuticals Inchistory →COM1.28%$26M600.0K
24ARVNArvinas Inchistory →COM1.24%$25M608.6K
252662247DiTeos Therapeutics Inchistory →COM1.22%$25M1.80M
26VKTXViking Therapeutics Inchistory →COM1.21%$25M300.0K
27ORICOric Pharmaceuticals Inchistory →COM1.18%$24M1.73M
28KURAKura Oncology Inchistory →COM1.05%$21M1.00M
29GONGeron Corphistory →COM0.98%$20M6.00M
30DAWNGBXDay One Biopharmaceuticals Ihistory →COM0.97%$20M1.19M
31Third Harmonic Bio IncCOM0.93%$19M2.00M
324XC1Kalvista Pharmaceuticals Inchistory →COM0.93%$19M1.59M
33ALLOAllogene Therapeutics Inchistory →COM0.85%$17M3.85M
34GPCRStructure Therapeutics Inchistory →SPONSORED ADS0.85%$17M400.0K
35Prothena Corp PLCSHS0.84%$17M690.0K
36SANASana Biotechnology Inchistory →COM0.76%$15M1.54M
37RLAYRelay Therapeutics Inchistory →COM0.75%$15M1.82M
38PSTXUSDPoseida Therapeutics Inchistory →COM0.71%$14M4.47M
39Engene Holdings IncCOM0.61%$12M727.9K
40PRLDPrelude Therapeutics Inchistory →COM0.60%$12M2.57M
41ELVNEnliven Therapeutics Inchistory →COM0.58%$12M671.4K
42IOVAIovance Biotherapeutics Inchistory →COM0.55%$11M750.0K
43JSPRJasper Therapeutics Inchistory →COM NEW0.51%$10M350.0K
44BOLDBoundless Bio Inchistory →COM0.50%$10M711.3K
45SYRESpyre Therapeutics IncCOM NEW0.47%$9M250.0K
46IPSCCentury Therapeutics IncCOM0.36%$7M1.75M
47ZNTLZentalis Pharmaceuticals IncCOM0.35%$7M450.0K
48AMLXAmylyx Pharmaceuticals IncCOM0.21%$4M1.50M
49ABSIABSCI CorporationCOM0.20%$4M700.0K
50ATRAGBXAtara Biotherapeutics IncCOM0.14%$3M4.15M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.